Harout Semerjian
Chief Executive Officer at GLYCOMIMETICS, INC.
Net worth: 42 750 $ as of 2024-04-29
Harout Semerjian active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GLYCOMIMETICS, INC. | Director/Board Member | 2021-08-05 | - |
| Chief Executive Officer | 2021-08-05 | - | |
| President | 2021-08-05 | - |
Career history of Harout Semerjian
Former positions of Harout Semerjian
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNOMEDICS, INC. | Director/Board Member | 2020-04-15 | 2020-05-26 |
| Chief Executive Officer | 2020-04-15 | 2020-05-26 | |
| President | 2020-04-15 | 2020-05-26 | |
| IPSEN | Corporate Officer/Principal | 2018-02-28 | 2020-03-31 |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Corporate Officer/Principal | - | - |
Training of Harout Semerjian
| Cornell University | Masters Business Admin |
| Queen's University | Masters Business Admin |
| Lebanese American University | Undergraduate Degree |
Statistics
International
| United States | 4 |
| France | 3 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| IPSEN | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
- Stock Market
- Insiders
- Harout Semerjian
- Experience
